BOSTON--(BUSINESS WIRE)--Biogen Idec today presented results from its Phase IIa trial of baminercept (LTßR-Ig or BG9924), the first dual-mechanism, lymphotoxin-ß (LT-ß) and LIGHT pathway inhibitor in development for the treatment of autoimmune diseases, including rheumatoid arthritis (RA). The data suggest clinically meaningful improvements in American College of Rheumatology (ACR) scores and individual core set measurements in patients with RA who received baminercept compared with placebo. Results from the Phase IIa trial were presented at ACR’s 73rd Annual Meeting in Boston.
